

# Oculopharyngeal Muscular Dystrophy (OPMD) Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/O106E46400B8EN.html>

Date: July 2022

Pages: 70

Price: US\$ 3,250.00 (Single User License)

ID: O106E46400B8EN

## Abstracts

Oculopharyngeal muscular dystrophy (OPMD) is a rare genetic muscle disorder with onset during adulthood most often between 40 and 60 years of age. OPMD is characterized by slowly progressive muscle disease (myopathy) affecting the muscles of the upper eyelids and the throat.

This report contains market size and forecasts of Oculopharyngeal Muscular Dystrophy (OPMD) in global, including the following market information:

Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Oculopharyngeal Muscular Dystrophy (OPMD) companies in 2021 (%)

The global Oculopharyngeal Muscular Dystrophy (OPMD) market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Tablets Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Oculopharyngeal Muscular Dystrophy (OPMD) include

Benitec Biopharma Inc., Bioblast Pharma, BioMarin, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd, Santhera Pharmaceuticals, Pfizer Inc. and Marathon Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Oculopharyngeal Muscular Dystrophy (OPMD) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Oculopharyngeal Muscular Dystrophy (OPMD) Market, By Type, 2017-2022, 2023-2028 (\$ Millions) & (K Units)

Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, By Type, 2021 (%)

Tablets

Capsules

Injectable

Other

Global Oculopharyngeal Muscular Dystrophy (OPMD) Market, By Application, 2017-2022, 2023-2028 (\$ Millions) & (K Units)

Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, By Application, 2021 (%)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Oculopharyngeal Muscular Dystrophy (OPMD) Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions) & (K Units)

Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

## Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Oculopharyngeal Muscular Dystrophy (OPMD) revenues in global market, 2017-2022 (Estimated), (\$ millions)

Key companies Oculopharyngeal Muscular Dystrophy (OPMD) revenues share in global market, 2021 (%)

Key companies Oculopharyngeal Muscular Dystrophy (OPMD) sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Oculopharyngeal Muscular Dystrophy (OPMD) sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Benitec Biopharma Inc.

Bioblast Pharma

BioMarin

PTC Therapeutics

NS Pharma

Nobelpharma Co., Ltd

Santhera Pharmaceuticals

Pfizer Inc.

Marathon Pharmaceuticals

Fibrogen

Bristol-Myers Squibb

Sarepta Therapeutics

GSK

## Contents

### **1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS**

- 1.1 Oculopharyngeal Muscular Dystrophy (OPMD) Market Definition
- 1.2 Market Segments
  - 1.2.1 Market By Type
  - 1.2.2 Market By Application
- 1.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
  - 1.5.1 Research Methodology
  - 1.5.2 Research Process
  - 1.5.3 Base Year
  - 1.5.4 Report Assumptions & Caveats

### **2 GLOBAL OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) OVERALL MARKET SIZE**

- 2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size: 2021 VS 2028
- 2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, Prospects & Forecasts: 2017-2028
- 2.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales: 2017-2028

### **3 COMPANY LANDSCAPE**

- 3.1 Top Oculopharyngeal Muscular Dystrophy (OPMD) Players in Global Market
- 3.2 Top Global Oculopharyngeal Muscular Dystrophy (OPMD) Companies Ranked by Revenue
- 3.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Companies
- 3.4 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Companies
- 3.5 Global Oculopharyngeal Muscular Dystrophy (OPMD) Price by Manufacturer (2017-2022)
- 3.6 Top 3 and Top 5 Oculopharyngeal Muscular Dystrophy (OPMD) Companies in Global Market, by Revenue in 2021
- 3.7 Global Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Product Type
- 3.8 Tier 1, Tier 2 and Tier 3 Oculopharyngeal Muscular Dystrophy (OPMD) Players in Global Market
  - 3.8.1 List of Global Tier 1 Oculopharyngeal Muscular Dystrophy (OPMD) Companies

### 3.8.2 List of Global Tier 2 and Tier 3 Oculopharyngeal Muscular Dystrophy (OPMD) Companies

## 4 SIGHTS BY PRODUCT

### 4.1 Overview

4.1.1 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size Markets, 2021 & 2028

4.1.2 Tablets

4.1.3 Capsules

4.1.4 Injectable

4.1.5 Other

4.2 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue & Forecasts

4.2.1 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2022

4.2.2 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2023-2028

4.2.3 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028

4.3 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales & Forecasts

4.3.1 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2022

4.3.2 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2023-2028

4.3.3 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028

4.4 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (Manufacturers Selling Prices), 2017-2028

## 5 SIGHTS BY APPLICATION

### 5.1 Overview

5.1.1 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2021 & 2028

5.1.2 Hospital Pharmacies

5.1.3 Retail Pharmacies

5.1.4 Online Pharmacies

5.2 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue &

## Forecasts

5.2.1 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2022

5.2.2 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2023-2028

5.2.3 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028

5.3 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales & Forecasts

5.3.1 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2022

5.3.2 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2023-2028

5.3.3 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028

5.4 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (Manufacturers Selling Prices), 2017-2028

## 6 SIGHTS BY REGION

6.1 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2021 & 2028

6.2 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue & Forecasts

6.2.1 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2022

6.2.2 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2023-2028

6.2.3 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028

6.3 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales & Forecasts

6.3.1 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2022

6.3.2 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2023-2028

6.3.3 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028

6.4 North America



6.4.1 By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028

6.4.2 By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028

6.4.3 US Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.4.4 Canada Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.4.5 Mexico Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.5 Europe

6.5.1 By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028

6.5.2 By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028

6.5.3 Germany Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.5.4 France Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.5.5 U.K. Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.5.6 Italy Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.5.7 Russia Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.5.8 Nordic Countries Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.5.9 Benelux Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.6 Asia

6.6.1 By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028

6.6.2 By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028

6.6.3 China Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.6.4 Japan Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.6.5 South Korea Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.6.6 Southeast Asia Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.6.7 India Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.7 South America

6.7.1 By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028

6.7.2 By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028

6.7.3 Brazil Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.7.4 Argentina Oculopharyngeal Muscular Dystrophy (OPMD) Market Size,

2017-2028

6.8 Middle East & Africa

6.8.1 By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028

6.8.2 By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028

6.8.3 Turkey Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.8.4 Israel Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.8.5 Saudi Arabia Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

6.8.6 UAE Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028

## **7 MANUFACTURERS & BRANDS PROFILES**

7.1 Benitec Biopharma Inc.

7.1.1 Benitec Biopharma Inc. Corporate Summary

7.1.2 Benitec Biopharma Inc. Business Overview

7.1.3 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings

7.1.4 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)

7.1.5 Benitec Biopharma Inc. Key News

7.2 Bioblast Pharma

7.2.1 Bioblast Pharma Corporate Summary

7.2.2 Bioblast Pharma Business Overview

7.2.3 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings

7.2.4 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)

7.2.5 Bioblast Pharma Key News

7.3 BioMarin

7.3.1 BioMarin Corporate Summary

7.3.2 BioMarin Business Overview

7.3.3 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings

7.3.4 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)

7.3.5 BioMarin Key News

7.4 PTC Therapeutics

7.4.1 PTC Therapeutics Corporate Summary

- 7.4.2 PTC Therapeutics Business Overview
- 7.4.3 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
- 7.4.4 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
- 7.4.5 PTC Therapeutics Key News
- 7.5 NS Pharma
  - 7.5.1 NS Pharma Corporate Summary
  - 7.5.2 NS Pharma Business Overview
  - 7.5.3 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
  - 7.5.4 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
  - 7.5.5 NS Pharma Key News
- 7.6 Nobelpharma Co., Ltd
  - 7.6.1 Nobelpharma Co., Ltd Corporate Summary
  - 7.6.2 Nobelpharma Co., Ltd Business Overview
  - 7.6.3 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
  - 7.6.4 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
  - 7.6.5 Nobelpharma Co., Ltd Key News
- 7.7 Santhera Pharmaceuticals
  - 7.7.1 Santhera Pharmaceuticals Corporate Summary
  - 7.7.2 Santhera Pharmaceuticals Business Overview
  - 7.7.3 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
  - 7.7.4 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
  - 7.7.5 Santhera Pharmaceuticals Key News
- 7.8 Pfizer Inc.
  - 7.8.1 Pfizer Inc. Corporate Summary
  - 7.8.2 Pfizer Inc. Business Overview
  - 7.8.3 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
  - 7.8.4 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
  - 7.8.5 Pfizer Inc. Key News
- 7.9 Marathon Pharmaceuticals

- 7.9.1 Marathon Pharmaceuticals Corporate Summary
- 7.9.2 Marathon Pharmaceuticals Business Overview
- 7.9.3 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
- 7.9.4 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
- 7.9.5 Marathon Pharmaceuticals Key News
- 7.10 Fibrogen
  - 7.10.1 Fibrogen Corporate Summary
  - 7.10.2 Fibrogen Business Overview
  - 7.10.3 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
  - 7.10.4 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
  - 7.10.5 Fibrogen Key News
- 7.11 Bristol-Myers Squibb
  - 7.11.1 Bristol-Myers Squibb Corporate Summary
  - 7.11.2 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Business Overview
  - 7.11.3 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
  - 7.11.4 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
  - 7.11.5 Bristol-Myers Squibb Key News
- 7.12 Sarepta Therapeutics
  - 7.12.1 Sarepta Therapeutics Corporate Summary
  - 7.12.2 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Business Overview
  - 7.12.3 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
  - 7.12.4 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
  - 7.12.5 Sarepta Therapeutics Key News
- 7.13 GSK
  - 7.13.1 GSK Corporate Summary
  - 7.13.2 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Business Overview
  - 7.13.3 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
  - 7.13.4 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)

### 7.13.5 GSK Key News

## **8 GLOBAL OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) PRODUCTION CAPACITY, ANALYSIS**

8.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity, 2017-2028

8.2 Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity of Key Manufacturers in Global Market

8.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Production by Region

## **9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS**

9.1 Market Opportunities & Trends

9.2 Market Drivers

9.3 Market Restraints

## **10 OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) SUPPLY CHAIN ANALYSIS**

10.1 Oculopharyngeal Muscular Dystrophy (OPMD) Industry Value Chain

10.2 Oculopharyngeal Muscular Dystrophy (OPMD) Upstream Market

10.3 Oculopharyngeal Muscular Dystrophy (OPMD) Downstream and Clients

10.4 Marketing Channels Analysis

10.4.1 Marketing Channels

10.4.2 Oculopharyngeal Muscular Dystrophy (OPMD) Distributors and Sales Agents in Global

## **11 CONCLUSION**

## **12 APPENDIX**

12.1 Note

12.2 Examples of Clients

12.3 Disclaimer

## List Of Tables

### LIST OF TABLES

- Table 1. Key Players of Oculopharyngeal Muscular Dystrophy (OPMD) in Global Market
- Table 2. Top Oculopharyngeal Muscular Dystrophy (OPMD) Players in Global Market, Ranking by Revenue (2021)
- Table 3. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Companies, (US\$, Mn), 2017-2022
- Table 4. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share by Companies, 2017-2022
- Table 5. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Companies, (K Units), 2017-2022
- Table 6. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Share by Companies, 2017-2022
- Table 7. Key Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Price (2017-2022) & (US\$/Unit)
- Table 8. Global Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Product Type
- Table 9. List of Global Tier 1 Oculopharyngeal Muscular Dystrophy (OPMD) Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 10. List of Global Tier 2 and Tier 3 Oculopharyngeal Muscular Dystrophy (OPMD) Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 11. By Type – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2021 & 2028
- Table 12. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US\$, Mn), 2017-2022
- Table 13. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US\$, Mn), 2023-2028
- Table 14. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2017-2022
- Table 15. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2023-2028
- Table 16. By Application – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2021 & 2028
- Table 17. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US\$, Mn), 2017-2022
- Table 18. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US\$, Mn), 2023-2028



Table 19. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2017-2022

Table 20. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2023-2028

Table 21. By Region – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2021 VS 2028

Table 22. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US\$, Mn), 2017-2022

Table 23. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US\$, Mn), 2023-2028

Table 24. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2017-2022

Table 25. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2023-2028

Table 26. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2017-2022

Table 29. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2023-2028

Table 30. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2022

Table 31. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2023-2028

Table 32. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2017-2022

Table 33. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2023-2028

Table 34. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2022

Table 35. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2023-2028

Table 36. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2017-2022

Table 37. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2023-2028

Table 38. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD)

Revenue, (US\$, Mn), 2017-2022

Table 39. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD)

Revenue, (US\$, Mn), 2023-2028

Table 40. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD)

Sales, (K Units), 2017-2022

Table 41. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD)

Sales, (K Units), 2023-2028

Table 42. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2022

Table 43. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2023-2028

Table 44. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2017-2022

Table 45. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2023-2028

Table 46. Benitec Biopharma Inc. Corporate Summary

Table 47. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings

Table 48. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 49. Bioblast Pharma Corporate Summary

Table 50. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings

Table 51. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 52. BioMarin Corporate Summary

Table 53. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings

Table 54. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 55. PTC Therapeutics Corporate Summary

Table 56. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings

Table 57. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 58. NS Pharma Corporate Summary

Table 59. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings

Table 60. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 61. Nobelpharma Co., Ltd Corporate Summary



- Table 62. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
- Table 63. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)
- Table 64. Santhera Pharmaceuticals Corporate Summary
- Table 65. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
- Table 66. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)
- Table 67. Pfizer Inc. Corporate Summary
- Table 68. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
- Table 69. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)
- Table 70. Marathon Pharmaceuticals Corporate Summary
- Table 71. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
- Table 72. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)
- Table 73. Fibrogen Corporate Summary
- Table 74. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
- Table 75. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)
- Table 76. Bristol-Myers Squibb Corporate Summary
- Table 77. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
- Table 78. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)
- Table 79. Sarepta Therapeutics Corporate Summary
- Table 80. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
- Table 81. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)
- Table 82. GSK Corporate Summary
- Table 83. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
- Table 84. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)
- Table 85. Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity (K Units) of Key Manufacturers in Global Market, 2020-2022 (K Units)
- Table 86. Global Oculopharyngeal Muscular Dystrophy (OPMD) Capacity Market Share

of Key Manufacturers, 2020-2022

Table 87. Global Oculopharyngeal Muscular Dystrophy (OPMD) Production by Region, 2017-2022 (K Units)

Table 88. Global Oculopharyngeal Muscular Dystrophy (OPMD) Production by Region, 2023-2028 (K Units)

Table 89. Oculopharyngeal Muscular Dystrophy (OPMD) Market Opportunities & Trends in Global Market

Table 90. Oculopharyngeal Muscular Dystrophy (OPMD) Market Drivers in Global Market

Table 91. Oculopharyngeal Muscular Dystrophy (OPMD) Market Restraints in Global Market

Table 92. Oculopharyngeal Muscular Dystrophy (OPMD) Raw Materials

Table 93. Oculopharyngeal Muscular Dystrophy (OPMD) Raw Materials Suppliers in Global Market

Table 94. Typical Oculopharyngeal Muscular Dystrophy (OPMD) Downstream

Table 95. Oculopharyngeal Muscular Dystrophy (OPMD) Downstream Clients in Global Market

Table 96. Oculopharyngeal Muscular Dystrophy (OPMD) Distributors and Sales Agents in Global Market

## List Of Figures

### LIST OF FIGURES

- Figure 1. Oculopharyngeal Muscular Dystrophy (OPMD) Segment By Type
- Figure 2. Oculopharyngeal Muscular Dystrophy (OPMD) Segment By Application
- Figure 3. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028 (US\$, Mn)
- Figure 7. Oculopharyngeal Muscular Dystrophy (OPMD) Sales in Global Market: 2017-2028 (K Units)
- Figure 8. The Top 3 and 5 Players Market Share by Oculopharyngeal Muscular Dystrophy (OPMD) Revenue in 2021
- Figure 9. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
- Figure 10. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
- Figure 11. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (US\$/Unit), 2017-2028
- Figure 12. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
- Figure 13. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
- Figure 14. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (US\$/Unit), 2017-2028
- Figure 15. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
- Figure 16. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
- Figure 17. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
- Figure 18. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
- Figure 19. US Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028
- Figure 20. Canada Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn),

2017-2028

Figure 21. Mexico Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 22. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028

Figure 23. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028

Figure 24. Germany Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 25. France Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 26. U.K. Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 27. Italy Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 28. Russia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 29. Nordic Countries Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 30. Benelux Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 31. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028

Figure 32. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028

Figure 33. China Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 34. Japan Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 35. South Korea Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 36. Southeast Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 37. India Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 38. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028

Figure 39. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028

Figure 40. Brazil Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 41. Argentina Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 42. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028

Figure 43. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028

Figure 44. Turkey Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 45. Israel Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 46. Saudi Arabia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 47. UAE Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US\$, Mn), 2017-2028

Figure 48. Global Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity (K Units), 2017-2028

Figure 49. The Percentage of Production Oculopharyngeal Muscular Dystrophy (OPMD) by Region, 2021 VS 2028

Figure 50. Oculopharyngeal Muscular Dystrophy (OPMD) Industry Value Chain

Figure 51. Marketing Channels

## I would like to order

Product name: Oculopharyngeal Muscular Dystrophy (OPMD) Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/O106E46400B8EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O106E46400B8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

